Characteristics and Mortality of Patients With Cancer Diagnosed With SARS-CoV-2 in Northern Portugal.

IF 1.6 4区医学 Q4 ONCOLOGY

Anticancer research Pub Date : 2025-04-01 DOI:10.21873/anticanres.17555

José Taveira-Barbosa, Teresa Garcia, Ana Lebre, Filipa Fontes, Mariana Brandão, Rita Calisto, Rubén Turé, Maria José Bento, Nuno Lunet, Samantha Morais, Luísa Lopes-Conceição

{"title":"Characteristics and Mortality of Patients With Cancer Diagnosed With SARS-CoV-2 in Northern Portugal.","authors":"José Taveira-Barbosa, Teresa Garcia, Ana Lebre, Filipa Fontes, Mariana Brandão, Rita Calisto, Rubén Turé, Maria José Bento, Nuno Lunet, Samantha Morais, Luísa Lopes-Conceição","doi":"10.21873/anticanres.17555","DOIUrl":null,"url":null,"abstract":"Background/aim: Patients with cancer have been found to be at higher risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, which may negatively affect their prognosis. This study aimed to compare sociodemographic and clinical characteristics, as well as mortality, between cancer patients with and without SARS-CoV-2 infection.Patients and methods: Patients with tumors of the esophagus, stomach, colon and rectum, pancreas, lung, skin-melanoma, breast, cervix, non-Hodgkin lymphoma, and leukemia diagnosed between March 2019 and March 2021, and followed at the Portuguese Oncology Institute of Porto (IPO-Porto) were identified. Patients with SARS-CoV-2 infection between March 2020 and September 2021 were compared to patients without infection. Vital status was assessed up to March 2024. Cox proportional hazards regression was used to estimate crude, age- and stage-adjusted hazard ratios (HRs) and 95% confidence intervals (95%CIs) for mortality.Results: During follow-up, one-third of patients who had SARS-CoV-2 died (vs. one-fourth), corresponding to an adjusted HR (95%CI) of 1.39 (1.03-1.88). Significantly higher adjusted HRs were observed for residents outside Porto's Metropolitan Area (HR=1.94, 95%CI=1.22-3.09), patients with lung cancer (HR=2.02, 95%CI=1.12-3.66) and patients with surgery as the first cancer treatment received at IPO-Porto (HR=2.00, 95%CI=1.08-3.74).Conclusion: Cancer patients with SARS-CoV-2 infection had higher mortality compared to those without infection, and specific subgroups of patients at higher risk were identified.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 4","pages":"1749-1760"},"PeriodicalIF":1.6000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17555","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: Patients with cancer have been found to be at higher risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, which may negatively affect their prognosis. This study aimed to compare sociodemographic and clinical characteristics, as well as mortality, between cancer patients with and without SARS-CoV-2 infection.

Patients and methods: Patients with tumors of the esophagus, stomach, colon and rectum, pancreas, lung, skin-melanoma, breast, cervix, non-Hodgkin lymphoma, and leukemia diagnosed between March 2019 and March 2021, and followed at the Portuguese Oncology Institute of Porto (IPO-Porto) were identified. Patients with SARS-CoV-2 infection between March 2020 and September 2021 were compared to patients without infection. Vital status was assessed up to March 2024. Cox proportional hazards regression was used to estimate crude, age- and stage-adjusted hazard ratios (HRs) and 95% confidence intervals (95%CIs) for mortality.

Results: During follow-up, one-third of patients who had SARS-CoV-2 died (vs. one-fourth), corresponding to an adjusted HR (95%CI) of 1.39 (1.03-1.88). Significantly higher adjusted HRs were observed for residents outside Porto's Metropolitan Area (HR=1.94, 95%CI=1.22-3.09), patients with lung cancer (HR=2.02, 95%CI=1.12-3.66) and patients with surgery as the first cancer treatment received at IPO-Porto (HR=2.00, 95%CI=1.08-3.74).

Conclusion: Cancer patients with SARS-CoV-2 infection had higher mortality compared to those without infection, and specific subgroups of patients at higher risk were identified.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Anticancer research 医学-肿瘤学

CiteScore

3.70

自引率

10.00%

发文量

566

审稿时长

2 months

期刊介绍： ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed. ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies). Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.